comparemela.com

EQS-News: Heidelberg Pharma AG


/ Key word: 9 Month figures





Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023






12.10.2023 /...

Related Keywords

Hungary ,Germany ,South Africa ,Switzerland ,Coted Ivoire ,Poland ,Pratteln ,Switzerland General ,Berlin ,Memorial Sloan Kettering Cancer Center ,New York ,United States ,Melbourne ,Victoria ,Australia ,Redhill ,Free State ,Thailand ,Frankfurt ,Brandenburg ,Neu Ulm ,Bayern ,Croatia ,Huadong ,Phichit ,Zagreb ,Grad ,Ivory Coast ,American ,Australian ,Walter Miller ,Sylvia Wimmer ,Jan Schmidt ,Eli Lilly ,Heidelberg Pharma ,Guanylyl Cyclase ,Access Program ,Santhera Pharmaceuticals ,Corporate Communications ,Heidelberg Pharma Group ,Investors Announcements ,Safety Review Committee ,Optimapharm Group ,Consortium For Enhanced Sepsis Outcomes ,Telix Pharmaceuticals ,Nuvisan Group ,Nuclear Defense ,Nasdaq ,Heidelberg Pharma Research Gmb ,Redhill Biopharma Ltd ,Good Laboratory Practice ,American Association For Cancer Research ,Frankfurt Stock Exchange ,Mc Services ,Merck Kga ,Early Access Program ,Merck Kgaa ,Interim Management Statement ,First Nine Months ,Jan Schmidt Brand ,Antibody Targeted Amanitin Conjugate ,American Association ,Cancer Research ,Executive Board ,Chief Financial ,Emergence Therapeutics ,Partner Takeda ,Antibody Targeted Amanitin ,Telix Pharmaceuticals Limited ,Expanded Access Program ,Early Access ,Enhanced Sepsis ,Joint Program Executive Office ,Heidelberg Pharma Research Gmbh ,Financial Reports ,Executive Management ,Markets ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.